Adenosine 3′,5′-cyclic monophosphate (cAMP)-dependent phosphoregulation of mitochondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors

Keyphrases

• 2′,3′-Dideoxycytidine 33%
• 3′-azido-3′-deoxythymidine 16%
• Complex I Activity 33%
• Cyclic Adenosine Monophosphate (cAMP) 100%
• Direct Interaction 16%
• DNA Polymerase Activity 16%
• Dose Effect 16%
• HepG2 Cells 16%
• Long-term Toxicity 16%
• Mitochondrial Bioenergetics 16%
• Mitochondrial Complex Activity 16%
• Mitochondrial Complex I 100%
• Mitochondrial Kinases 16%
• Mitochondrial Respiration 16%
• Monophosphate 33%
• NDUFB11 16%
• Nucleoside Reverse Transcriptase Inhibitors 100%
• Observed Effects 16%
• Oxidoreductase Activity 16%
• Phosphoprotein 16%
• Phosphoregulation 100%
• Phosphorylation 50%
• PKA Activity 16%
• Protein Phosphorylation 16%
• Succinate 33%
• Superoxide Production 66%

Neuroscience

• Cyclic Adenosine Monophosphate 100%
• Didanosine 16%
• DNA Polymerase 16%
• Kinase 16%
• Mitochondrial Respiration 16%
• NADH Dehydrogenase (Ubiquinone) 100%
• Nucleoside Analog 83%
• Phosphoprotein 16%
• Protein Phosphorylation 16%
• Reverse Transcriptase Inhibitors 83%
• Reverse-Transcriptase Inhibitor 100%
• Staining Technique 16%
• Succinate 33%
• Thymidine 16%
• Zalcitabine 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Adenosine 100%
• Didanosine 16%
• DNA Polymerase 16%
• Nucleoside Analog 83%
• Oxidoreductase 16%
• Phosphoprotein 16%
• Phosphotransferase 16%
• Reduced Nicotinamide Adenine Dinucleotide Dehydrogenase (Ubiquinone) 100%
• RNA Directed DNA Polymerase Inhibitor 100%
• Succinic Acid 33%
• Superoxide 66%
• Thymidine 16%
• Zalcitabine 33%